Telavancin
A vancomycin derivative with a second way to kill bacteria
Telavancin is a lipoglycopeptide antibiotic made from vancomycin. It blocks bacterial cell-wall building and also damages the bacterial membrane. Approved as Vibativ in 2009, it is given once daily by infusion for complicated skin infections and, when other options are unsuitable, Staphylococcus aureus pneumonia.
What is it?
Telavancin belongs to the lipoglycopeptides, vancomycin relatives with a fatty side chain, alongside dalbavancin and oritavancin. Like vancomycin it blocks the building of the bacterial cell wall, and its side chain also disrupts the bacterial membrane. It acts against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA).
In the ATLAS programme of 1,867 patients with complicated skin infections, success was 88% on telavancin and 87% on vancomycin, and cure in MRSA infections was 91% against 86%. In two pneumonia trials totalling 1,503 patients, cure rates were similar overall (58.9% against 59.5%), but mortality was higher with telavancin in patients with pre-existing kidney impairment. In patients with mixed Gram-positive and Gram-negative pneumonia, cure rates favoured vancomycin.
That finding produced a boxed warning for increased mortality in pneumonia patients with moderate or severe kidney impairment, alongside warnings for kidney toxicity and potential harm in pregnancy. The label reserves its pneumonia use for when alternatives are not suitable. Its half-life is about 8 hours.
At a Glance
Every value in this table is printed from the Grey Peptides dataset, the same record the compound explorer and comparison tool read, so the three can never disagree.
Half-Life: How Much Remains
The dataset records a half-life of terminal half-life about 8 hours (8.0 single dose, 8.1 multiple doses) for Telavancin. After each half-life, half of what was in the circulation is gone, so about 3% remains after five. Real clearance varies with the person, the dose, the route and kidney or liver function; this is arithmetic on a published figure, not a dosing tool.
Published Research
The trials behind telavancin, from their PubMed abstracts.
ATLAS: complicated skin infections
In 1,867 patients, clinical success was 88% on telavancin and 87% on vancomycin; among 579 patients with MRSA, cure was 91% against 86% and microbiological eradication 90% against 85%.
ATTAIN: hospital-acquired pneumonia
In 1,503 patients, cure rates were 58.9% on telavancin and 59.5% on vancomycin overall, higher with telavancin in monomicrobial S. aureus infection; mortality in one study was 21.5% against 16.6%.
Telavancin's place
A review of telavancin as a semi-synthetic lipoglycopeptide with a dual mechanism against resistant Gram-positive bacteria, summarising its clinical trials and its kidney-related safety limits.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
Warnings from the Vibativ label (DailyMed, effective December 19, 2025).
Legal Status
Telavancin is an approved prescription drug in the US.
Frequently Asked Questions
?Is telavancin a peptide?
Yes, in the broad sense: like vancomycin it is a glycopeptide, a cross-linked peptide core carrying sugars, here with an added fatty side chain.
?Why does telavancin have a boxed warning?
In pneumonia trials, patients with pre-existing moderate or severe kidney impairment had higher mortality on telavancin than on vancomycin. The label also warns of kidney toxicity and potential harm in pregnancy.
?How does it compare with vancomycin?
In large trials it matched vancomycin for skin infections and pneumonia overall, with somewhat higher cure rates against MRSA in skin infections.
?How is telavancin given?
By intravenous infusion over 60 minutes once every 24 hours, for 7 to 14 days for skin infections and 7 to 21 days for pneumonia, with the dose adjusted for kidney function, according to the label.
?Is telavancin safe in pregnancy?
The label's boxed warning says it may cause fetal harm, based on adverse developmental outcomes in three animal species at clinically relevant doses, and advises verifying pregnancy status before starting and effective contraception during treatment.
References
- [fda] US FDA, Drugs@FDA (openFDA): VIBATIV, NDA 022110 (September 11, 2009) and NDA 022407 (June 21, 2013). Read October 3, 2026.
- [fda-pi] FDA. Vibativ (telavancin) US prescribing information (DailyMed set 5359b759-db7c-4672-9e8a-59c93869bd91, effective December 19, 2025). Read October 3, 2026.
- [clinical-trial] Stryjewski ME, et al. "Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms." Clin Infect Dis, 2008;46(11):1683-93. PMID: 18444791.
- [clinical-trial] Rubinstein E, et al. "Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens." Clin Infect Dis, 2011;52(1):31-40. PMID: 21148517.
- [pubmed] Das B, et al. "Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens." Ther Adv Infect Dis, 2017;4(2):49-73. PMID: 28634536.
Sources & Citations
Studies were read from their PubMed records; regulatory sources are listed below, read October 3, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Consult a licensed healthcare provider before making health decisions.